Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Injection in Advanced Solid Tumors
NCT07784777Phase 1Not yet recruiting
- Sponsor
- BOE Technology Group
- Start
- Sep 2026
- Primary completion
- Sep 2027
01
Overview
Phase 1, open-label, single-arm trial of NK cell therapy (Anhui Provincial Hospital) in solid tumor (advanced stage), sponsored by BOE Technology Group. Primary endpoints: Dose-limiting toxicity at 21 days, Maximum tolerated dose and recommended Phase II dose at 24 months and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07784777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784777.